Flagship Harbor Advisors, LLC Editas Medicine, Inc. Transaction History

Flagship Harbor Advisors, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 08, 2021	SELL	$27.07 - $84.35 $3,140 - $9,784	-116 Closed	0 $0
Q3 2019 Oct 22, 2019	SELL	$22.49 - $26.81 $3,373 - $4,021	-150 Reduced 56.39%	116 $2,000
Q2 2019 Jul 22, 2019	SELL	$20.48 - $27.76 $3,768 - $5,107	-184 Reduced 40.89%	266 $6,000
Q1 2019 Apr 15, 2019	SELL	$19.43 - $26.41 $971 - $1,320	-50 Reduced 10.0%	450 $11,000
Q2 2018 Aug 14, 2018	BUY	$31.4 - $41.01 $15,700 - $20,505	500 New	500 $17,000

228

54.2M

412K

355K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Flagship Harbor Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Flagship Harbor Advisors, LLC with notifications on news.